Francone M, Bucciarelli-Ducci C*, Carbone I, Canali E, Scardala R, Calabrese F, Sardella G, Mancone M, Catalano C, Fedele F, Passariello R, Bogaert J**

Slides:



Advertisements
Similar presentations
STEM-AMI OUTCOME TRIAL STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial   A national, multicentre, randomised, open-label, Phase.
Advertisements

CMR of Non-ischemic Dilated and Restrictive Cardiomyopathies
1 The GRACIA – 2 Trial (GRupo de Análisis de la Cardiopatía Isquémica Aguda) Randomised trial comparing Primary PCI versus Facilitated Intervention (TNK.
Cardiac Arrhythmia in Thalassaemia Limassol, 24 – 26 October 2012 Malcolm Walker University College and the Heart Hospitals, London Clinical Director Hatter.
Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
Dysfunctional but viable myocardium Ischemic heart disease assessed by MRI and SPECT Martin Ugander, MD Department of Clinical Sciences, Lund Department.
Trial profile Fox K et al. Lancet 2008;372:
Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
Clinical Trial Results. org C. Michael Gibson, M.S., M.D. Director TIMI Data Coordinating Center Invasive Cardiologist Beth Israel Deaconess Medical Center.
The Impact of Regional ST-Elevation Myocardial Infarction Systems of Care on the Use of Protocols and Quality Improvement Initiatives in Community Hospitals.
The Impact of Regional ST-Elevation Myocardial Infarction Systems of Care on the Use of Protocols and Quality Improvement Initiatives in Community Hospitals.
Murat Sezer, Emre Aslanger, Arif Cimen, Ebru Yormaz, Cuneyt Turkmen, Berrin Umman, Yılmaz Nisanci, Zehra Bugra and Sabahattin Umman Istanbul University,
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Minimise the damage – Pre- and Post-conditioning Dr Derek J Hausenloy The Hatter Cardiovascular Institute, University College London, UK. Myocardial Recovery.
ATTEMPT study: pooled-Analysis of Trials on ThrombEctomy in acute Myocardial infarction based on individual PatienT data CLINICAL TRIAL UPDATE III ESC.
Angiographic Estimates of Myocardium at Risk During Acute Myocardial Infarction: a Validation Study Using Cardiac MRI José T. Ortiz, Sheridan N. Meyers,
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Myocardial Ischaemia National Audit Project Are we replacing good fibrinolytic treatment with poor primary PCI? John Birkhead who has NO CONFLICT OF INTEREST.
The index of microvascular resistance measured acutely predicts infarct severity and left ventricular function at 3 months in patients with ST segment.
The Impact of Thrombus Aspiration on 1-year Mortality in Primary PCI for ST-Elevation Myocardial Infarction, ACSIS 2010 Experience Mady Moriel, Shlomi.
Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
Jay H Traverse, MD Principal Investigator, LateTIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
A Randomized, Double-blind, Placebo-controlled Trial of Intravenous Erythropoietin in Patients with ST-Segment Elevation Myocardial Infarction – Primary.
Serviço de Cardiologia Hospital de Santa Maria Centro Hospitalar Lisboa Norte Subclinical focal fibrosis and abnormal strain in patients with sarcoidosis.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Intravenous Erythropoietin in Patients with ST-Segment Elevation MI -- Study performed by: Najjar et al -- Presented by: Jay Hall PA-SII, Ali Rahimi MD.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Remote Ischemic Conditioning Reduces Myocardial.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Long Term Benefit Of Early Pre-reperfusion Metoprolol Administration In Patients With Acute Myocardial Infarction: Results From The METOCARD-CNIC trial.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
Search strategy and results Amir Kashani, et al. Circulation. 2006;114:
“How we do” CMR in acute myocardial infarction
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
British Society of Cardiovascular Magnetic Resonance
The NHLBI TIME Trial: Role of Microvascular Obstruction in 2-Year Clinical and MRI Follow-up Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis.
Establishing a research network of cardiac MRI centers to investigate cardioprotection in STEMI patients Derek Hausenloy Professor, Cardiovascular and.
Revascularization in Patients With Left Ventricular Dysfunction:
Left ventricular thrombus formation after acute myocardial infarction as assessed by cardiovascular magnetic resonance imaging  Ronak Delewi, Robin Nijveldt,
What about CMR in patients with acute MI?
EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.
Thomas Stiermaier, MD; Suzanne de Waha, MD;
Dr Heerajnarain Bulluck Research fellow
Giuseppe Biondi Zoccai
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Figure 2 Ischaemic and bleeding outcomes in the major clinical trials
Figure 1 PCI strategies in patients with STEMI and multivessel disease
Time Is Myocardium and the Wavefront of Necrosis
Published in the European Heart Journal
Global Registry of Acute Coronary Events: GRACE
Brian R. Weil et al. BTS 2017;2: Brief Myocardial Ischemia Produces Transient LV Dysfunction Consistent With Stunned Myocardium A 10-min total left.
Infarct Size after Primary Angioplasty Patients With Bivalirudin
(A) Meta-analysis of repeat revascularisation in randomised trials.
European Heart Journal Advance Access
Evolution of Myocardial Blush after MI
Upper row shows myocardial infarction with MVO (−IMH) (indicated by arrows) on pathology (A), T2-STIR (B), late gadolinium enhancement (LGE) images (C)
A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
Distribution of left atrial (LA) remodel.
Presentation transcript:

Francone M, Bucciarelli-Ducci C*, Carbone I, Canali E, Scardala R, Calabrese F, Sardella G, Mancone M, Catalano C, Fedele F, Passariello R, Bogaert J** and Agati L Impact Of Primary Coronary Angioplasty Delay On Myocardial Salvage, Infarct Size And Microvascular Damage in Patients with ST-Elevation Myocardial Infarction: Insight From Cardiovascular Magnetic Resonance *Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London, United Kingdom **Leuven University, Belgium Umberto I Hospital, University “La Sapienza”, Rome, Italy

Time is muscle De Luca, Circulation 2004 Background

Challenges Background What happens to the muscle? How to recognize salvageable myocardium? How much salvageable myocardium is there?

Background Kim RJ et al, Circulation 1999 Aletras AH et al, Circulation 2006 Rochitte C et al, Circulation 1998 MICROVASCULAR DAMAGE MYOCARDIAL NECROSIS MYOCARDIUM AT RISK

Aims of the Study 1.To investigate the correlation between the extent and the nature of myocardial damage in relation to different time-to- reperfusion intervals 2.To investigate the relationship between time-to-reperfusion intervals, myocardial damage and subsequent LV remodeling

Study Protocol n=70 STEMI, primary PCI ≤90min n=19 >90-150min n=17 > min n=17 >360min n=17 Time-to-reperfusion

CMR Protocol Cine 6 months3±2 days

CMR Protocol 3±2 days T2 wT1 w gadolinium increased signal intensity (myocardial edema) Myocardium at risk increased signal intensityreduced signal intensity Infarct SizeMicrovascular Obstruction

Results: Myocardium at Risk Myocardial Edema (% LV) Time to reperfusion (min) p=0.37

Results: Infarct Size Infarct Size (% LV) Time to reperfusion (min) p=0.005 * * p=0.002

Myocardium at Risk – Infarct size Time to reperfusion (min)

Myocardial Salvage (%) Time to reperfusion (min) p=0.003 * * p=0.001

Microvascular Obstruction MVO (% LV) Time to reperfusion (min) p=0.04 * * p=0.001

EDV: Baseline ≤90 min> min> min>360 min Time to reperfusion (min) EDV (ml) p=0.03

EDV: Baseline vs 6 Months ≤90 min> min> min>360 min Time to reperfusion (min) EDV (ml) p=0.002 p=0.005 p=0.05 p=0.003 Baseline 6 months

ESV: Baseline ≤90 min> min> min>360 min Time to reperfusion (min) ESV (ml) p=0.02

ESV: Baseline vs 6 Months ≤90 min> min> min>360 min Time to reperfusion (min) ESV (ml) p=0.003 p=0.006 p=0.001 p=0.06 Baseline 6 months

EF: Baseline ≤90 min> min> min>360 min Time to reperfusion (min) EF (%) p=0.06

EF: Baseline vs 6 Months ≤90 min> min> min>360 min Time to reperfusion (min) EF (%) p=0.04 p=ns p=0.04 Baseline 6 months

LAD Infarctions ≤90 min> min> min>360 min Time to reperfusion (min) * MVO Myocardium at Risk Infarct Size

Non-LAD Infarctions ≤90 min> min> min>360 min Time to reperfusion (min) * MVO Myocardium at Risk Infarct Size

Conclusions-1  First in-vivo, clinical, non invasive evaluation of the consequences of early and delayed coronary reperfusion on myocardial damage

Conclusions-2  Time is muscle Longer time-to-reperfusion (>360min) Less salvaged myocardium Larger infarct size and more MVO LV remodeling  Myocardial salvage, infarct size and MVO by CMR surrogate endpoints for clinical trials assessing the efficacy of reperfusion strategies